The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data

BackgroundAdebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab (...

Full description

Bibliographic Details
Main Authors: Bi-Cheng Wang, Chen Fu, Guo-He Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
PD-L1 inhibitor
survival
first-line
extensive-stage
small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185577/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185577/full

Similar Items